Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy

doi:10.4239/wjd.v16.i6.104665

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (199)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-1)

Sum=191

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=1

Jun 15, 2025 (publication date) through Jun 16, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Jun 15, 2025; 16(6): 104665
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.104665

Open in New Tab Full Size Figure Download Figure

Figure 1 The primary signaling pathways and key regulatory factors of ferroptosis. TF: Transferrin; TFR1: Transferrin receptor1; DMT1: Divalent 311 metal transporter 1; ACSL4: Acyl-CoA synthetase long-chain family member 4; LPCAT3: Lysophosphatidylcholine acyltransferase 3; LOX: Lipoxygenase; SLC3A2: Solute carrier family 3 member 2; SLC7A11: Solute carrier family 7 member 11; GCL: Glutamate cysteine ligase; GSS: Glutathione synthase; Cys: Cystine; Glu: Glutamate; Gly: Glycine; NADPH: Nicotinamide adenine dinucleotide phosphate; ROS: Reactive oxygen species; PUFA: Polyunsaturated fatty acid; PUFA-PL: Polyunsaturated fatty acid-phospholipid; GPX4: Glutathione peroxidase; GSH: Glutathione.

Open in New Tab Full Size Figure Download Figure

Figure 2 Pathophysiological mechanism of diabetic cardiomyopathy. AGEs: Advanced glycation end products; RAAS: Renin-angiotensin-aldosterone system; DCM: Diabetic cardiomyopathy.

Open in New Tab Full Size Figure Download Figure

Figure 3 The regulatory role of ferroptosis in diabetic cardiomyopathy. Nrf2: Nuclear factor erythroid 2-related factor 2; SLC40A1: Solute carrier family 40 member 1; NCOA4: Nuclear receptor coactivator 4; TF: Transferrin; TFR1: Transferrin receptor1; DMT1: Divalent 311 metal transporter 1; ACSL4: Acyl-CoA synthetase long-chain family member 4; LPCAT3: Lysophosphatidylcholine acyltransferase 3; LOX: Lipoxygenase; SLC3A2: Solute carrier family 3 member 2; SLC7A11: Solute carrier family 7 member 11; GCL: Glutamate cysteine ligase; GSS: Glutathione synthase; Cys: Cystine; Glu: Glutamate; Gly: Glycine; ROS: Reactive oxygen species; PUFA: Polyunsaturated fatty acid; PUFA-PL: Polyunsaturated fatty acid-phospholipid; GPX4: Glutathione peroxidase; GSH: Glutathione; ARE: Antioxidant response elements.

Citation: Li GZ, Liu JY, Zhou H. Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy. World J Diabetes 2025; 16(6): 104665
URL: https://www.wjgnet.com/1948-9358/full/v16/i6/104665.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i6.104665